ZEOX (Zeo ScientifiX) Cyclically Adjusted Revenue per Share: $1.07 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZEOX Zeo ScientifiX Inc ZEOX
56 GF Score
Price $1.94
GF Value $2.66
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zeo ScientifiX Cyclically Adjusted Revenue per Share?

Zeo ScientifiX ZEOX 56 Cyclically Adjusted Revenue per Share is $1.07 as of Apr. 2026. GuruFocus rates ZEOX with a GF Score™ of 56/100 and a GF Value™ of $2.66 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zeo ScientifiX's adjusted revenue per share for the three months ended in Apr. 2026 was $0.333. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.07 for the trailing ten years ended in Apr. 2026.

During the past 12 months, Zeo ScientifiX's average Cyclically Adjusted Revenue Growth Rate was 7.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zeo ScientifiX was 14.90% per year. The lowest was 7.50% per year. And the median was 11.20% per year.

As of today (2026-07-16), Zeo ScientifiX's current stock price is $1.94. Zeo ScientifiX's Cyclically Adjusted Revenue per Share for the quarter that ended in Apr. 2026 was $1.07. Zeo ScientifiX's Cyclically Adjusted PS Ratio of today is 1.81.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zeo ScientifiX was 31.06. The lowest was 1.00. And the median was 2.54.


Zeo ScientifiX  (OTCPK:ZEOX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zeo ScientifiX's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.94/1.07
=1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zeo ScientifiX was 31.06. The lowest was 1.00. And the median was 2.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zeo ScientifiX Cyclically Adjusted Revenue per Share Related Terms


Zeo ScientifiX Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zeo ScientifiX's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zeo ScientifiX Cyclically Adjusted Revenue per Share Chart

Zeo ScientifiX Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.82 0.90 1.00 1.02

Zeo ScientifiX Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.02 1.02 1.03 1.07

ZEOX vs JUNS, HOOK, LEXX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Zeo ScientifiX's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Cyclically Adjusted PS Ratio falls into.


ZEOX
56GF Score
Zeo ScientifiX Inc ZEOX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zeo ScientifiX Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zeo ScientifiX's adjusted Revenue per Share data for the three months ended in Apr. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=0.333/333.0200*333.0200
=0.333

Current CPI (Apr. 2026) = 333.0200.

Zeo ScientifiX Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201607 0.050 240.628 0.069
201610 0.063 241.729 0.087
201701 0.002 242.839 0.003
201704 0.261 244.524 0.355
201707 0.300 244.786 0.408
201710 0.472 246.663 0.637
201801 0.748 247.867 1.005
201804 0.144 250.546 0.191
201807 0.102 252.006 0.135
201810 0.114 252.885 0.150
201901 0.080 251.712 0.106
201904 0.160 255.548 0.209
201907 0.243 256.571 0.315
201910 0.233 257.346 0.302
202001 0.276 257.971 0.356
202004 0.218 256.389 0.283
202007 0.209 259.101 0.269
202010 0.222 260.388 0.284
202101 0.283 261.582 0.360
202104 0.227 267.054 0.283
202107 0.248 273.003 0.303
202110 0.298 276.589 0.359
202201 0.302 281.148 0.358
202204 0.322 289.109 0.371
202207 0.315 296.276 0.354
202210 0.218 298.012 0.244
202301 0.153 299.170 0.170
202304 0.116 303.363 0.127
202307 0.172 305.691 0.187
202310 0.202 307.671 0.219
202401 0.186 308.417 0.201
202404 0.183 313.548 0.194
202407 0.174 314.540 0.184
202410 0.189 315.664 0.199
202501 0.172 317.671 0.180
202504 0.181 320.795 0.188
202507 0.204 323.048 0.210
202510 0.253 0.000
202601 0.206 325.252 0.211
202604 0.333 333.020 0.333

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.07 mean?
Zeo ScientifiX (ZEOX) has a Cyclically Adjusted Revenue per Share of $1.07 as of Apr. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zeo ScientifiX and its competitors.
Is Zeo ScientifiX's Cyclically Adjusted Revenue per Share too high?
Zeo ScientifiX's current Cyclically Adjusted Revenue per Share is $1.07. Overall, Zeo ScientifiX has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Cyclically Adjusted Revenue per Share compare to JUNS and HOOK?
Zeo ScientifiX's Cyclically Adjusted Revenue per Share of $1.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zeo ScientifiX and its competitors. Zeo ScientifiX's current Cyclically Adjusted Revenue per Share is $1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.66, compared to a current price of $1.94 — trading 27.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.07. Zeo ScientifiX's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Cyclically Adjusted Revenue per Share is $1.07 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zeo ScientifiX (ZEOX) Overvalued in 2026?

Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued. The current stock price of $1.94 is trading 27.1% below its estimated GF Value™ of $2.66. GuruFocus considers Zeo ScientifiX to be Modestly Undervalued.

Key valuation signals for ZEOX:

  • Cyclically Adjusted Revenue per Share: $1.07
  • GF Value™: $2.66 vs. price of $1.94 (27.1% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zeo ScientifiX Business Description

Address 3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
56GF Score

Get the complete analysis for ZEOX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.94
Price
$2.66
GF Value